Hutchison China MediTech Ltd – (NASDAQ:HCM) has been given a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that provide coverage for the stock, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy rating.
Analysts have set a one year consensus target price of $41.00 for the company, according to Zacks. Zacks has also assigned Hutchison China MediTech an industry rank of 166 out of 265 based on the ratings given to related companies.
A number of research firms have weighed in on HCM. BidaskClub downgraded shares of Hutchison China MediTech from a “buy” rating to a “hold” rating in a research report on Tuesday, March 20th. Zacks Investment Research downgraded shares of Hutchison China MediTech from a “hold” rating to a “sell” rating in a research report on Thursday, March 15th.
A number of large investors have recently added to or reduced their stakes in the business. Castleark Management LLC acquired a new stake in Hutchison China MediTech during the 4th quarter valued at approximately $177,000. Geode Capital Management LLC acquired a new stake in Hutchison China MediTech during the 4th quarter valued at approximately $258,000. Folger Hill Asset Management LP increased its position in Hutchison China MediTech by 12.6% during the 4th quarter. Folger Hill Asset Management LP now owns 60,342 shares of the company’s stock valued at $2,379,000 after purchasing an additional 6,772 shares during the period. Perceptive Advisors LLC acquired a new stake in Hutchison China MediTech during the 3rd quarter valued at approximately $273,000. Finally, Mckinley Capital Management LLC Delaware acquired a new stake in Hutchison China MediTech during the 4th quarter valued at approximately $1,237,000. 7.46% of the stock is owned by institutional investors and hedge funds.
Hutchison China MediTech Company Profile
Hutchison China MediTech Limited, a biopharmaceutical company, engages in the research, development, manufacture, and sale of pharmaceuticals and healthcare products primarily in the People's Republic of China and Hong Kong. It operates through Innovation Platform and Commercial Platform segments.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Hutchison China MediTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hutchison China MediTech and related companies with MarketBeat.com's FREE daily email newsletter.